MedPath
Found 80 clinical trials|View Analysis
Sort by:

Clinical Study of Low-dose Interval Radiotherapy Combined With Tirelizumab and SOX Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 2
Not yet recruiting
Conditions
Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Interventions
Radiation: Neoadjuvant Therapy(5×3Gy radiotherapy)
Drug: Neoadjuvant Therapy(tirelizumab, oxaliplatin, S-1)
Procedure: Surgical treatment
Drug: Adjuvant therapy(SOX chemotherapy)
First Posted Date
2025-01-09
Last Posted Date
2025-01-09
Lead Sponsor
Shandong Provincial Hospital
Target Recruit Count
32
Registration Number
NCT06766578

A Multiple Tumor Species, Open and Multi-center Clinical Study of Alpaloritovorelli Antibodies (QL-1706) Combined with Pulsed Low Dose Rate External Irradiation (PLDR) for Disease Progression After Previous Anti-tumor Therapy

Phase 1
Not yet recruiting
Conditions
Esophageal Cancer
Non Small Cell Lung Cancer
Cervical Cancer
Interventions
Radiation: Pulsed low dose rate radiotherapy (PLDR)
Drug: Alpaloritovorelli antibodies
First Posted Date
2025-01-07
Last Posted Date
2025-01-07
Lead Sponsor
Anhui Provincial Hospital
Target Recruit Count
90
Registration Number
NCT06760676

Low-dose Radiotherapy Combined with Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC

Phase 1
Not yet recruiting
Conditions
Extensive-stage Small-cell Lung Cancer
Interventions
Radiation: Low-dose radiotherapy
Drug: Tifcemalimab injection
Drug: Toripalimab
Drug: Cisplatin
Drug: Carboplatin
Drug: Etoposide
First Posted Date
2024-12-13
Last Posted Date
2024-12-27
Lead Sponsor
Sichuan University
Target Recruit Count
12
Registration Number
NCT06732258

Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC

Phase 2
Recruiting
Conditions
NSCLC
Neoadjuvant Immunotherapy
Low Dose Radiotherapy
Sintilimab
Interventions
Drug: Active comparator
Radiation: Experimental
First Posted Date
2024-12-04
Last Posted Date
2024-12-04
Lead Sponsor
Anhui Provincial Cancer Hospital
Target Recruit Count
86
Registration Number
NCT06714708
Locations
🇨🇳

Anhui Provinvial Cancer Hospital, Hefei, Anhui, China

GEP Combined With Radiotherapy in Non-locally Treatable Recurrent NPC

Phase 2
Not yet recruiting
Conditions
Nasopharynx Cancer
Interventions
Drug: GEP (Gemcitabine, Recombinant Human Endostatin, and Carrellizumab) Combined With High-low-dose Radiotherapy
First Posted Date
2024-09-25
Last Posted Date
2024-09-25
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
41
Registration Number
NCT06611826

Fruquintinib Combined With Adebrelimab and High and Low Dose Radiotherapy in the Treatment of Second-line and Above Failure MSS Metastatic Colorectal Cancer.

Not Applicable
Recruiting
Conditions
MSS Metastatic Colorectal Cancer
Interventions
First Posted Date
2024-09-25
Last Posted Date
2024-09-25
Lead Sponsor
Ningbo Medical Center Lihuili Hospital
Target Recruit Count
30
Registration Number
NCT06613113
Locations
🇨🇳

Kaitai Liu, Ningbo, Zhejiang, China

Evaluating the Efficacy and Safety of Adebrelimab in Combination with Chemotherapy and LDRT As 1L Treatment for ES-SCLC

Phase 3
Not yet recruiting
Conditions
Small Cell Lung Cancer Extensive Stage
Interventions
Drug: Adebrelimab
Drug: Chemotherapy
Radiation: low dose radiotherapy
First Posted Date
2024-09-24
Last Posted Date
2024-09-24
Lead Sponsor
Sichuan University
Target Recruit Count
202
Registration Number
NCT06610734

Low-Dose Involved-Field Radiotherapy Plus Mmunochemotherapy for ESCC

Phase 2
Recruiting
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Immunotherapy
Interventions
Radiation: low-dose involved-field radiotherapy combined with immunochemotherapy
First Posted Date
2024-09-19
Last Posted Date
2024-12-03
Lead Sponsor
Sichuan University
Target Recruit Count
41
Registration Number
NCT06603402
Locations
🇨🇳

West China Hospital of Sichuan University, Chengdu, Sichuan, China

Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer

Phase 2
Recruiting
Conditions
Microsatellite Stable Metastatic Colorectal Cancer
Interventions
Drug: standard systemic therapy combined with high/low-dose radiotherapy plus toripalimab
First Posted Date
2024-07-29
Last Posted Date
2024-07-29
Lead Sponsor
Fudan University
Target Recruit Count
96
Registration Number
NCT06525428
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

The Treatment of Ocular Adnexal Extranodal Marginal Zone B-cell Lymphoma by Orelabrutinib and Radiotherapy

Phase 2
Recruiting
Conditions
Extranodal Marginal Zone B-cell Lymphoma
Interventions
Drug: Orelabrutinib
Radiation: Ultra-low dose radiotherapy
First Posted Date
2024-07-16
Last Posted Date
2024-07-22
Lead Sponsor
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Target Recruit Count
50
Registration Number
NCT06503276
Locations
🇨🇳

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath